Pembro in “TMB high” (10+) cancers - paper published in Lancet Oncol. No difference in OS between TMB high and TMB low. Neverthelessless FDA approved. SMH. @OncoAlert
Friendly reminder that surrogate endpoints like PFS only reduce study time by an average of 11 months - @IamEmchee, et al. 🙂 We shouldn’t proclaim new therapies as “new standard of care”, without showing OS or QOL benefit for patients. #ASCO2020#asco20 https://t.co/rERjHZpb6Q
Couldn’t agree more, would like to tell my patients how a new therapy will directly help them. “Surrogate End Points and Patient-Reported Outcomes for Novel Oncology Drugs” https://t.co/jMUDFvU5qw
@docamitgs @NDP1001 @nicole_rich8 Beautiul study, May report too, curious about if DAA reduces mortality but has similar recurrent HCC, then would receipt of DAA influence survival outcome of adjuvant/consolidation systemic treatment (if ongoing trials are +)? What’s the HR in usual survival curve/Cox regression?
Wow amazing online course that changed how I think about oncology drugs, and completed just in time before my first day as faculty tomorrow @edxonline#mooc https://t.co/TSpac3YAkr
I look forward to a response and hope Dr. @ScottGottliebMD will rectify his mistake & resign from his position at @Pfizer. It would send a strong message about the importance of integrity of current & former federal officials.
Health policy conundrum, 1) gets cancer drug approved faster but more uncertainty 2) might not get drug approved but more certainty of clinical benefit https://t.co/nlaYDoNSUI
On interpreting #clinicaltrials: When you hear “A HR of __ & a __month diff in PFS,” consider what the control arm is. The interpretation of those #s differs if comparator is placebo/BSC or active control, & if active control, if new drug is an add on or replacement tx. #ASCO19
ANNOUNCE failed to meet OS primary endpoint and Olaratumab will be withdrawn after previous initial FDA @US_FDA approval. #ASCO19#ASCO2019#sarcoma#pdgfra
In light of today’s #ASCO19 plenary, please read our latest @JAMAInternalMed paper on accelerated approval to understand this pathway’s trade offs. We even managed to sneak in a sentence about #olaratumab at the very last moment. https://t.co/VLUPRmK8b8 #ASCOplenary#sarcoma
The biggest honor, however, is to have 2 editorials accompany our paper. I always lamented @RichardLehman1 ‘s retiring from BMJ blogs without getting chance to read his comment on my work. But now he has written an editorial instead with @cpgYALE . https://t.co/sQePfbrPDh 🙏